Market Overview - The U.S. stock market experienced a significant rebound on November 21, 2025, with major indexes closing higher, recovering from earlier losses driven by optimism regarding potential interest rate cuts by the Federal Reserve [1][4] - The Dow Jones Industrial Average (DJI) rose 1.4%, adding 650 points, while the S&P 500 (SPX) gained 1.4%, closing at 6,590 points, and the Nasdaq Composite (IXIC) increased by 1.5% [2] Federal Reserve Influence - New York Federal Reserve President John Williams indicated support for a potential interest rate cut "in the near term," which shifted market expectations significantly, raising the likelihood of a rate cut at the December meeting to 73.1% from 39.1% [4] Corporate Performance - Nvidia (NVDA) reported a 62% year-over-year revenue increase to $57 billion, but its shares fell 3.2% on Thursday and 1.7% on Friday due to concerns over AI valuations [5] - Walmart (WMT) saw its stock decline by approximately 2% on Friday after a strong performance on Thursday, where it had jumped 6.5% following better-than-expected third-quarter results [6] - Retailers like Gap (GPS) and Ross Stores (ROST) had positive performances, with Gap surging 9.5% and Ross jumping 8.5% due to strong earnings [7] Notable Stock Movements - Alphabet (GOOGL) increased by over 3%, while Meta Platforms (META) added 1%. In contrast, Microsoft (MSFT) shares fell approximately 1%, and Oracle (ORCL) slid more than 4% [8] Upcoming Earnings and Economic Data - Several companies, including BJ's Wholesale Club Holdings (BJ) and IES Holdings (IESC), reported earnings after the market closed, with BJ's EPS at $1.16 against a forecast of $1.10 [9][10] - The upcoming week will feature key economic data releases, including the Producer Price Index (PPI) and Retail Sales for September, which were delayed due to a government shutdown [12]

Core Insights - Azenta, Inc. reported an earnings per share (EPS) of $0.21, matching estimates, and revenue of approximately $159.2 million, exceeding the estimated revenue of about $156.4 million [1][6] Financial Performance - For Q4 ending September 30, 2025, Azenta experienced a 6% year-over-year revenue increase, with a 4% organic growth [2][6] - The full fiscal year 2025 saw a 4% revenue increase, with a 3% organic rise, and an adjusted EBITDA margin expansion of 310 basis points compared to the previous year [2] Future Outlook - Azenta anticipates organic revenue growth between 3% and 5% for fiscal year 2026, along with an adjusted EBITDA margin expansion of approximately 300 basis points [3] - The company described fiscal 2025 as transformative, highlighting core revenue growth of 3% and significant margin expansion [3] Financial Stability - Azenta maintains a strong liquidity position with a current ratio of approximately 2.96, indicating nearly three times more current assets than current liabilities [4] - The debt-to-equity ratio stands at about 0.03, reflecting a low level of debt relative to equity [4] Valuation Metrics - The enterprise value to sales ratio is approximately 2.12, while the enterprise value to operating cash flow ratio is around 15.03, indicating the company's valuation relative to its revenue and operating cash flow [5] - Azenta expects to generate higher free cash flow in the coming year, signaling potential for future growth [5]

Financial Data and Key Metrics Changes - In Q4 2025, revenue was $159 million, up 6% year-over-year and up 4% organically, with full-year revenue at $594 million, reflecting a 4% increase on a reported basis and 3% organic growth [14][15][16] - Non-GAAP EPS for Q4 was $0.21 and $0.51 for the full year, with adjusted EBITDA margin at 13% for Q4 and 11.2% for the full year, representing an expansion of approximately 230 basis points in Q4 and 310 basis points for the full year [14][15][16] - Free cash flow for the full year was $38 million, a notable improvement of $26 million year-over-year, with $546 million in cash, cash equivalents, and marketable securities at year-end [15][20] Business Line Data and Key Metrics Changes - Sample Management Solutions (SMS) revenue was $86 million for Q4, up 2% reported and flat organically, with a non-GAAP gross margin of 49.3%, up 180 basis points year-over-year [17] - Multi-Omix segment delivered record revenue of $73 million in Q4, representing 11% growth on a reported basis and 10% organic growth, driven by a 50% year-over-year increase in sequencing volume [18][19] Market Data and Key Metrics Changes - The macro environment remains volatile, with softer academic and NIH funding impacting growth, particularly in the U.S. market [9][10] - The company anticipates core revenue growth between 3%-5% for fiscal 2026, with expected adjusted EBITDA margin expansion of 300 basis points [11][21] Company Strategy and Development Direction - The company has implemented the Azenta Business System (ABS) to enhance operational efficiency and accountability, focusing on driving productivity, organic growth, and targeted M&A [8][10] - The strategic focus includes reinvesting savings into innovation, sales, marketing, and product management, with a commitment to value creation and operational excellence [8][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating macroeconomic uncertainties and capitalizing on opportunities arising from customer consolidation and outsourcing trends [9][10] - The company is entering fiscal 2026 from a position of strength, with a clear focus on delivering core growth and margin expansion [11][22] Other Important Information - The results exclude B Medical Systems, which is treated as discontinued operations, with an additional non-cash loss of $4 million recorded in Q4 [13] - The company plans to host an Investor Day to outline its multi-year growth strategy and capital deployment priorities [11][22] Q&A Session Summary Question: Guidance on growth and market conditions - Management noted that the market is expected to grow at 1%-2%, with a focus on delivering results for the full year despite a challenging first half due to capital expenditure slowdowns and government funding impacts [25][26][28] Question: Update on SMS growth and backlog - Management expressed confidence in mid-single-digit growth for SMS, supported by a strong backlog and new leadership driving commercial initiatives [29][30] Question: Insights on customer bases and macro conditions - Management highlighted strength in the pharma sector, with ongoing clarity around projects, while noting some delays in academic and government spending due to the recent government shutdown [39][40] Question: Expectations for M&A and market growth - The company is focused on tuck-in acquisitions to expand its core business, particularly in SRS and automated solutions, with a bullish outlook for 2026 [70][71] Question: Performance expectations for automated stores - Management indicated that while the automated stores segment is currently experiencing low single-digit growth, investments in R&D are expected to yield positive results in the long term [72][73]

Financial Data and Key Metrics Changes - In Q4 2025, revenue was $159 million, up 6% year-over-year, and up 4% organically, with full-year revenue at $594 million, reflecting a 4% increase on a reported basis and 3% organic growth [14][15] - Non-GAAP EPS for Q4 was $0.21, and $0.51 for the full year, with adjusted EBITDA margin at 13% for Q4 and 11.2% for the full year, representing an expansion of approximately 230 basis points in Q4 and 310 basis points for the full year [14][15] - Free cash flow for the full year was $38 million, a notable improvement of $26 million year-over-year, with $546 million in cash, cash equivalents, and marketable securities at year-end [15][20] Business Line Data and Key Metrics Changes - Sample Management Solutions (SMS) revenue was $86 million for Q4, up 2% reported and flat organically, with a non-GAAP gross margin of 49.3%, up 180 basis points year-over-year [17][18] - Multi-Omix segment delivered record revenue of $73 million in Q4, representing 11% growth on a reported basis and 10% organic growth, driven by a 50% year-over-year increase in sequencing volume [18][19] Market Data and Key Metrics Changes - The macro environment remains volatile, with softer academic and NIH funding impacting growth, particularly in the U.S. market [9][10] - The company anticipates organic revenue growth of 3%-5% for fiscal 2026, with expectations of a decline of approximately 1%-2% in Q1 due to capital expenditure slowdowns and government shutdown impacts [21][60] Company Strategy and Development Direction - The company has implemented the Azenta Business System (ABS) to enhance operational efficiency and accountability, focusing on driving productivity, organic growth, and targeted M&A [8][10] - Strategic priorities include embedding ABS deeper across the organization, optimizing capital deployment, and continuing to deliver core growth and margin expansion [11][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating macroeconomic uncertainties and highlighted opportunities arising from customers consolidating partners and investing in automation [9][10] - The company is well-positioned for fiscal 2026, with a focus on operational excellence and a strong balance sheet to support growth initiatives [11][22] Other Important Information - The results exclude B Medical Systems, which is treated as discontinued operations, with an additional non-cash loss of $4 million recorded in Q4 [13] - The company plans to host an Investor Day to outline its multi-year growth strategy and capital deployment priorities [11][21] Q&A Session Summary Question: Guidance on growth expectations and market conditions - Management noted that the market is expected to grow at 1-2%, with capital expenditure slowdowns impacting growth, particularly in the U.S. [25][26] Question: Update on SMS growth and backlog - Confidence in mid-single-digit growth for SMS is supported by a strong backlog and recent investments in commercial initiatives [29][30] Question: Insights on macroeconomic trends affecting customer bases - Management highlighted strength in pharma spending, with some projects being put on hold but showing signs of recovery [38][40] Question: Expectations for M&A activity - The company is focused on tuck-in acquisitions to expand its core business, particularly in SRS and automated solutions [69][70]

Financial Data and Key Metrics Changes - In Q4 2025, revenue was $159 million, up 6% year-over-year and up 4% organically, with full-year revenue at $594 million, reflecting a 4% increase on a reported basis and 3% organically [12][14] - Non-GAAP EPS for Q4 was $0.21, and for the full year, it was $0.51, with adjusted EBITDA margin at 13% for Q4 and 11.2% for the full year, representing an expansion of approximately 230 basis points in Q4 and 310 basis points for the full year [13][14] - Free cash flow for the full year improved by $26 million year-over-year, totaling $38 million, with $546 million in cash, cash equivalents, and marketable securities at year-end [14][19] Business Line Data and Key Metrics Changes - Sample Management Solutions (SMS) revenue was $86 million for Q4, up 2% reported and flat organically, with a non-GAAP gross margin of 49.3%, up 180 basis points year-over-year [16] - Multi-Omix segment achieved record revenue of $73 million in Q4, representing 11% growth on a reported basis and 10% organic growth, driven by a 50% year-over-year increase in sequencing volume [17] - Overall, Multi-Omix gross margin for Q4 was 43.7%, down 260 basis points year-over-year, primarily due to product mix and lower volume in certain areas [18] Market Data and Key Metrics Changes - The macro environment remains volatile, with softer academic and NIH funding impacting growth, particularly in the U.S. market [8][9] - The company anticipates organic revenue growth of 3%-5% for fiscal 2026, with Multi-Omix expected to deliver low single-digit growth and SMS contributing mid-single-digit growth [20][21] Company Strategy and Development Direction - The company has implemented the Azenta Business System (ABS) to enhance operational efficiency and accountability, focusing on driving productivity, organic growth, and targeted M&A [6][7] - The strategic focus includes reinvesting savings into innovation, sales, marketing, and product management, with a commitment to operational excellence and value creation [7][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating macroeconomic uncertainties and highlighted opportunities arising from customer consolidation and outsourcing trends [9][10] - The company is entering fiscal 2026 from a position of strength, with a clear focus on core growth and margin expansion, despite anticipated challenges in the first half of the year [10][21] Other Important Information - The results exclude B Medical Systems, which is treated as discontinued operations, with an additional non-cash loss of $4 million recorded in Q4 [11] - The company plans to host an Investor Day to outline its multi-year growth strategy and capital deployment priorities [10][21] Q&A Session Summary Question: Guidance on growth expectations and market conditions - Management noted that the macroeconomic slowdown and capital expenditure constraints are impacting growth, particularly in the U.S., with expectations of a 1-2% market growth [24][25] Question: Update on SMS growth and backlog - Confidence in mid-single-digit growth for SMS is supported by a strong backlog and recent commercial investments [29][30] Question: Insights on customer spending trends - Management highlighted strength in pharma spending, with some projects being reactivated post-restructuring [36] Question: Clarification on multi-omics growth expectations - Multi-Omix is expected to normalize to mid-single-digit growth due to price and volume adjustments [38] Question: M&A strategy and focus areas - The company is looking at tuck-in acquisitions to expand its core business, particularly in SRS and automated solutions [63][64]

Conference Call Fiscal Fourth Quarter and Full Year 2025 Financial Results November 21, 2025 © 2025 Azenta, Inc. • All rights reserved 1 1 Safe Harbor Statement "Safe Harbor" Statement under the U.S. Private Securities Litigation Reform Act of 1995; certain matters in this presentation, including forecasts of future demand and future Company performance, are forward- looking statements that are subject to risks and uncertainties that could cause actual results to materially differ, either better or worse, f ...

Revenue Performance - Q4 2025 reported revenue was $159 million, up 6% year over year, with organic revenue growth of 4%[2] - FY 2025 revenue totaled $594 million, representing a 4% increase year over year, with organic revenue growth of 3%[9] - Multiomics revenue for Q4 2025 was $73 million, an 11% increase year over year, with organic growth of 10%[9] - Sample Management Solutions revenue for FY 2025 was $325 million, up 2% year over year, with organic revenue growth of 1%[9] - Total revenue for the three months ended September 30, 2025, was $159,192 thousand, an increase of 5.3% compared to $150,604 thousand for the same period in 2024[23] - Total revenue for the year ended September 30, 2025, reached $325 million, a 2% increase from $319 million in 2024[48] - The company experienced a currency exchange rate impact of -1% on total revenue for the year ended September 30, 2025[48] Profitability Metrics - Adjusted EBITDA for FY 2025 was $66 million, with an adjusted EBITDA margin of 11.2%, an improvement of 310 basis points year over year[16] - Operating income for Q4 2025 was $2 million, with an operating margin of 1.2%, an improvement of 430 basis points year over year[9] - Adjusted operating income for Q4 2025 was $9 million, with an adjusted operating margin of 5.7%, an improvement of 60 basis points year over year[9] - GAAP operating income for the quarter ended September 30, 2025, was $8,015,000, compared to $7,503,000 for the same period in 2024, representing an increase of 6.8%[44] - Non-GAAP adjusted operating income for the year ended September 30, 2025, was $27,550,000, significantly higher than $11,106,000 in 2024, indicating a growth of 147.5%[44] Net Income and Earnings Per Share - Diluted EPS from continuing operations for Q4 2025 was $1.11, compared to a loss of $0.04 in the prior year[9] - Net income for the three months ended September 30, 2025, was $47,137 thousand, a significant recovery from a net loss of $6,639 thousand in the prior year[23] - Basic net income per share for the three months ended September 30, 2025, was $1.03, compared to a loss of $0.14 per share in the same period of 2024[23] - Net income from continuing operations for Q4 2025 was $50,853, compared to a loss of $331 in Q3 2025 and a loss of $1,745 in Q4 2024[30] - For the year ended September 30, 2025, net income from continuing operations was $23,658, a significant improvement from a loss of $24,366 in the previous year[31] Cash and Balance Sheet - The company ended FY 2025 with a total balance of cash and marketable securities of $546 million[16] - Cash and cash equivalents at the end of the period were $279,783 thousand, slightly down from $280,030 thousand a year earlier[25] - Total assets decreased to $2,056,854 thousand as of September 30, 2025, from $2,100,265 thousand in 2024[25] - Total liabilities remained relatively stable at $333,608 thousand compared to $332,418 thousand in the previous year[25] - The company reported a net cash provided by operating activities of $72,181 thousand for the year ended September 30, 2025, compared to $49,743 thousand in 2024[28] Transformation and Costs - The company is focused on long-term benefits through transformation costs aimed at cost reduction and productivity improvement, which are part of the 2024 cost reduction plan[41] - Transformation costs for Q4 2025 amounted to $634, down from $1,542 in Q3 2025 and $4,568 in Q4 2024[30] - Transformation costs for the year ended September 30, 2025, amounted to $2,820,000, up from $395,000 in 2024, reflecting increased investment in strategic projects[46] - The company incurred merger and acquisition costs of $87 in Q4 2025, compared to $58 in Q3 2025 and $52 in Q4 2024[30] Gross Profit and Margins - Gross profit for the year ended September 30, 2025, was $270,280 thousand, up from $254,622 thousand in 2024, reflecting a gross margin improvement[23] - GAAP gross profit for the quarter ended September 30, 2025, was $72,274 thousand, representing a 45.4% margin, compared to $66,404 thousand (46.2%) in the previous quarter and $68,487 thousand (45.5%) in the same quarter last year[40] - Non-GAAP adjusted gross profit for the same quarter was $74,362 thousand, or 46.7%, up from $68,497 thousand (47.6%) in the previous quarter and $70,728 thousand (47.0%) year-over-year[40] - For the year ended September 30, 2025, GAAP gross profit totaled $270,280 thousand, with a margin of 45.5%, compared to $254,622 thousand (44.4%) for the previous year[42] - Non-GAAP adjusted gross profit for the year was $278,315 thousand, or 46.9%, compared to $263,045 thousand (45.9%) in the prior year[42]

Core Viewpoint - Azenta, Inc. reported a transformative fiscal year 2025 with significant revenue growth and margin expansion, positioning the company for continued growth in fiscal 2026 [3][5]. Financial Performance - For Q4 2025, revenue from continuing operations was $159 million, a 6% increase year-over-year, with organic growth of 4% [2][6]. - Full year revenue for fiscal 2025 reached $594 million, up 4% year-over-year, with organic revenue growth of 3% [2][6]. - Adjusted EBITDA for Q4 2025 was $21 million, representing a 29% increase from the previous year, with an adjusted EBITDA margin of 13.0% [2][6]. - The company achieved a diluted EPS from continuing operations of $1.11 for Q4 2025, compared to a loss of $0.04 in the same quarter last year [2][6]. Segment Performance - Sample Management Solutions generated $86 million in revenue for Q4 2025, a 2% increase year-over-year, while Multiomics revenue was $73 million, up 11% year-over-year [2][6]. - For the full year, Sample Management Solutions revenue was $325 million, a 2% increase, and Multiomics revenue was $269 million, up 6% year-over-year [2][6]. Management Insights - The CEO highlighted the company's streamlined structure and focus on customer needs, projecting core growth of 3% to 5% and approximately 300 basis points of adjusted EBITDA margin expansion for fiscal 2026 [3][5]. - The company emphasized improvements in quality, delivery, and productivity as key drivers of its recent success [3]. Cash and Liquidity - As of September 30, 2025, Azenta had a total balance of cash, cash equivalents, restricted cash, and marketable securities amounting to $546 million [2][6]. Guidance - Azenta expects organic revenue growth for fiscal 2026 to be in the range of 3% to 5%, along with an anticipated adjusted EBITDA margin expansion of approximately 300 basis points [5][6].

Core Insights - Azenta, Inc. operates in the life sciences sector, focusing on sample exploration and management solutions, and was rebranded from Brooks Automation in December 2021 [1] - The company has two main segments: Life Sciences Products and Life Sciences Services, serving clients such as pharmaceutical and biotechnology companies, biorepositories, and research institutes [1] Financial Performance - The financial outlook for Azenta is positive, with a stable consensus price target of $38, while Evercore ISI has set a more optimistic target of $62 [2][3] - Azenta reported a 36% increase in third-quarter earnings per share (EPS), indicating strong operational performance [2][3] Future Expectations - The upcoming fiscal fourth quarter and full year 2025 earnings report, scheduled for November 21, 2025, is highly anticipated and will provide insights into the company's financial health and growth potential [4] - Leadership under President and CEO John Marotta and CFO Lawrence Lin positions Azenta favorably for continued success in the life sciences sector [4]

Core Viewpoint - Azenta, Inc. will announce its fiscal fourth quarter and full year 2025 earnings on November 21, 2025, before market opens [1]. Financial Results Announcement - The company will host a conference call and live webcast to discuss its financial results on the same day at 8:30 a.m. Eastern Time, accessible via the Azenta website [2]. - A replay of the conference call will be available starting at 8:30 a.m. ET on November 22, 2025 [2]. Company Overview - Azenta, Inc. is a leading provider of life sciences solutions, facilitating breakthroughs and therapies to market faster [3]. - The company offers a comprehensive suite of cold-chain sample management solutions and multiomics services, serving top pharmaceutical, biotech, academic, and healthcare institutions globally [3]. - Azenta operates under several industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey [3]. Operational Footprint - Azenta is headquartered in Burlington, MA, with operations across North America, Europe, and Asia [4]. Upcoming Events - The company will host an Investor Day at its biorepository facility in Indianapolis, Indiana, on December 10, 2025 [5].